Trial Profile
An open-label study of LentiGlobin BB305 in paediatric patients with beta thalassaemia major
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Betibeglogene-autotemcel (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- 07 Aug 2015 According to bluebird bio media release, NIH RAC review of HGB-207 (see 700257159) and HGB-208 study protocols in adult and adolescent patients with beta-thalassemia major and pediatric patients with beta-thalassemia major, respectively have been completed.
- 21 May 2015 New trial record
- 19 May 2015 bluebird bio plans to pursue conditional and accelerated registration strategies in EU and US, respectively. Company filed clinical study protocol for HGB-208 study with the NIH Recombinant DNA Advisory Committee (RAC) and was notified that HGB-208 study protocol is scheduled for public review on June 9, 2015. The data from this and three other studies (HGB-205, HGB-207 and HGB-208) will support the Biologics License Application (BLA) submission for LentiGlobin BB305.